# Recombinant Human Relaxin (rhRlx) in Pregnant Women Scheduled for Induction of Labor

> **NCT00259103** · PHASE2 · COMPLETED · sponsor: **Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies** · enrollment: 72 (actual)

## Conditions studied

- Labor, Induced

## Interventions

- **DRUG:** Serelaxin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00259103
- **Lead sponsor:** Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2014-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00259103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00259103, "Recombinant Human Relaxin (rhRlx) in Pregnant Women Scheduled for Induction of Labor". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00259103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*